Sagimet Biosciences Inc Dossier
Qualitative Analysis
Business overview
Sagimet Biosciences Inc. (NASDAQ: SGMT) is a clinical-stage biopharmaceutical company focused on the research, development, and commercialization of novel fatty acid synthase (FASN) inhibitors. The company targets dysfunctional metabolic and fibrotic pathways that result from the overproduction of palmitate, a key fatty acid. Sagimet's lead clinical program is denifanstat, an oral, once-daily selective FASN inhibitor being developed for metabolic dysfunction-associated steatohepatitis (MASH) and dermatologic conditions, specifically moderate-to-severe acne. The company's pipeline also includes TVB-3567, a second oral FASN inhibitor currently in Phase 1 clinical development for acne. Sagimet operates as a single business segment dedicated to advancing its FASN inhibitor platform.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Strategic prioritization of the dermatology pipeline, specifically advancing denifanstat and TVB-3567 for the treatment of moderate to severe acne.
Expected impact: Positions the company to capture a share of the large, underserved moderate to severe acne market with a novel, non-antibiotic oral mechanism of action.
Development of a fixed-dose combination (FDC) of denifanstat and resmetirom to target metabolic dysfunction-associated steatohepatitis (MASH) with F4 fibrosis.
Expected impact: Addresses a critical unmet medical need in advanced liver disease using complementary therapeutic pathways.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Grants Ascletis an exclusive license to develop and commercialize denifanstat in the Greater China territory, accelerating development in a major global market.
Terms: Initiated in January 2019, the partnership has the potential to generate up to $122 million in development and commercial milestones for Sagimet, in addition to double-digit royalties on net sales.
Grants Sagimet a global, exclusive license to innovative forms of resmetirom active pharmaceutical ingredient (API) developed by TAPI to support Sagimet's fixed-dose combination (FDC) program with denifanstat.
Terms: Exclusive global license covering technical evaluation, manufacture, and potential development of the FDC product.